Mutant is a research blend of three peptides in one lyophilized vial: TB-500, BPC-157 and KPV. Each component has its own published research, mostly from animal and cell models. Very little research has looked at these compounds together.
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Components
| Component | Amount per vial | What it is |
|---|---|---|
| TB-500 | 10 mg | Synthetic peptide derived from thymosin beta-4 |
| BPC-157 | 10 mg | 15-amino-acid synthetic peptide |
| KPV | 10 mg | Tripeptide Lys-Pro-Val |
TB-500
TB-500 is a synthetic peptide derived from thymosin beta-4, a protein involved in actin binding and cell migration. It has been studied in animal models of tendon, wound and tissue repair. The name is not used consistently across the literature and suppliers. Some use it for a short fragment of thymosin beta-4 and others for the full protein, so check the sequence on the COA. TB-500 research overview
BPC-157
BPC-157 is a 15-amino-acid fragment of a protein first described in gastric juice. It has been studied mainly in rodent gut, tendon, ligament and blood-vessel models, mostly by one research group. Human data are limited to small pilot reports. BPC-157 research overview
KPV
KPV (Lys-Pro-Val) is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied mainly in mouse models of intestinal inflammation (chemically induced colitis) and in intestinal cell cultures. That work suggests the peptide is taken up through the PepT1 transporter. Several groups have also studied nanoparticle delivery of KPV in these models. KPV research overview
Research on the combination
No published study has tested TB-500, BPC-157 and KPV together. The data for each component come from separate studies, using different models and conditions, and they should not be combined to predict how the blend behaves.
The only paired data we know of is one 2026 rat study of BPC-157 and TB-500 in Achilles tendon repair (Biçer et al., Joint Diseases and Related Surgery). It compared each peptide alone and both together. The authors called their results exploratory and reported no added effect from the combination over either peptide alone. KPV was not part of that study.
Limits of the evidence
- Almost all data on each component are preclinical (animal and cell models).
- There are no published data on this three-part blend.
- None of the three components is approved by the FDA for any use. BPC-157 and TB-500 are on the World Anti-Doping Agency’s Prohibited List.
Forms OmegAmino supplies
| Form | Contents |
|---|---|
| Lyophilized powder | One vial: 10 mg TB-500, 10 mg BPC-157, 10 mg KPV |
Every batch is third-party tested for identity and purity. You can look up the Certificate of Analysis for the Mutant blend we supply at omegamino-coas.com. Read more about how we test.
Storage
Store lyophilized peptide sealed and refrigerated, kept cool, dark and away from moisture. We don’t recommend home freezers: their defrost cycles warm and cool the contents repeatedly, which can damage peptides. Once reconstituted, keep the solution refrigerated and use it within the period your protocol specifies.
Related research
- TB-500
- BPC-157
- KPV
- GLOW Blend (GHK-Cu, BPC-157 and TB-500)
- All research overviews
Researchers with an approved account can order from the shop.
